CervoMed’s stock craters 77% after failed trial of treatment for rare brain disease
CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with dementia with Lewy bodies, or DLB, failed to meet its main goals.
